Travere Therapeutics, Inc.
US ˙ NasdaqGM ˙ US89422G1076

SecurityTVTX / Travere Therapeutics, Inc.
InstitutionCanada Pension Plan Investment Board
Latest Disclosed Ownership8,100 shares
Latest Disclosed Value $ 240,651
Canada Pension Plan Investment Board reports 10.99% decrease in ownership of TVTX / Travere Therapeutics, Inc.

On May 15, 2026 - Canada Pension Plan Investment Board filed a 13F-HR form disclosing ownership of 8,100 shares of Travere Therapeutics, Inc. (US:TVTX) valued at $240,651 USD as of March 31, 2026. The entity filed a previous 13F-HR on February 17, 2026 disclosing 9,100 shares of Travere Therapeutics, Inc.. This represents a change in shares of -10.99% during the quarter. The current value of the position is $366,120 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F TRAVERE THERAPEUTICS COM 89422G107 8,100 -1,000 -10.99 241 -30.84 0.0002
2026-02-17 2025-12-31 13F TRAVERE THERAPEUTICS COM 89422G107 9,100 9,100 348 0.0002
2024-05-14 2024-03-31 13F TRAVERE THERAPEUTICS Common Stock 89422G107 0 -224,000 -100.00 0 -100.00
2024-02-14 2023-12-31 13F TRAVERE THERAPEUTICS Common Stock 89422G107 224,000 0 0.00 2,014 0.55 0.0025
2023-11-09 2023-09-30 13F TRAVERE THERAPEUTICS Common Stock 89422G107 224,000 224,000 2,003 0.0029
2022-08-12 2022-06-30 13F TRAVERE THERAPEUTICS Common Stock 89422G107 0 -731,000 -100.00 0 -100.00
2022-05-13 2022-03-31 13F TRAVERE THERAPEUTICS Common Stock 89422G107 731,000 220,000 43.05 18,838 18.77 0.0253
2022-02-14 2021-12-31 13F TRAVERE THERAPEUTICS Common Stock 89422G107 511,000 53,000 11.57 15,861 42.80 0.0168
2021-11-15 2021-09-30 13F TRAVERE THERAPEUTICS Common Stock 89422G107 458,000 100,000 27.93 11,107 112.66 0.0126
2021-11-16 2021-06-30 13F/A-1 TRAVERE THERAPEUTICS Common Stock 89422G107 358,000 358,000 5,223 0.0062
2021-08-16 2021-06-30 13F TRAVERE THERAPEUTICS Common Stock 89422G107 358,000 358,000 5,223 0.0062
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.